Research & Trials
- Participate in a Clinical Trial
- Brain Bank
- Clinical Studies Explained
Clinical trial and study information is updated periodically. Trials listed on this page may be closed. To confirm clinical trial or study availability, contact:
Jody Corey-Bloom, M.D., Ph.D.
Phone: 858-249-0568
Email: jcoreybloom@ucsd.edu
KINECT-HD (Neurocrine) is a randomized, multicenter, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of the orally active VMAT2 inhibitor Valbenazine in Huntington's Disease patients that present with active chorea.
ENROLLING NOW: The purpose of the study is to evaluate the efficacy and safety of Valbenazine compared with placebo in HD subjects.
PROOF-HD is a randomized, multicenter, double-blind, placebo controlled, phase III study, conducted by Prilenia Therapeutics, evaluating the efficacy and safety of Pridopidine in patients with early stage HD.
ENROLLING NOW: The purpose of the study is to evaluate the efficacy, safety, biomarker effects, and functional maintenance of Pridopidine compared with placebo in subjects with early stage HD.
Triplet's SHIELD-HD study is a observational study that is investigating how Huntington's Disease progresses over time.
ENROLLMENT CLOSED: The purpose of the study is to observe disease progression for patients with varying manifestations of Huntington's Disease. Key findings may be used to help researchers initiate genetic therapies for HD.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease.
ENROLLMENT CLOSED: The purpose of the study is to evaluate the efficacy, safety, and biomarker effects of RG6042 compared with placebo in subjects with Huntington's disease.
VACCINEX is a Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503
ENROLLMENT CLOSED: The purpose of this study is to assess the safety and efficacy of monthly IV administration of a single dosage of VX15/2503 in Huntington's disease.
OMEROS: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Sequential, Cohort Study to Evaluate Safety and Efficacy of OMS643762 in Subjects with Huntington’s Disease
STUDY COMPLETED
Pride-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
STUDY COMPLETED
Reach2HD: A randomized, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington disease.
STUDY COMPLETED
SIENABIOTECH: Open-label Food Effect Study With SEN0014196 in Subjects With Huntington’s Disease
STUDY COMPLETED
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
ENROLLING NOW: A longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.